Precision BioSciences Activates First FUNCTION-DMD Site, Patient Screening Opens

What happened

Precision BioSciences announced the activation of the first clinical trial site and the opening of patient screening/enrollment for PBGENE-DMD in the Phase 1/2 FUNCTION-DMD study for Duchenne muscular dystrophy. This milestone converts the FDA IND clearance obtained in February 2026 into tangible operational progress, aligning with the company's guidance to activate a first U.S. site in 1H26. While first patient dosing has not been confirmed, the timeline remains on track for late-Q1/early-Q2 2026. The DMD program now serves as a second catalyst stream alongside the upcoming HBV biopsy update, broadening the clinical narrative. However, the stock's valuation remains heavily dependent on the HBV biopsy data due by mid-2026, and sustained DMD execution—including initial dystrophin expression data by YE26—is required to maintain momentum.

Implication

DMD proof-of-concept in humans remains to be seen; dystrophin expression data expected year-end 2026 is the key value inflection. Success would establish a dual-pipeline company, but failure to dose quickly or safety issues would undermine the thesis.

Thesis delta

The news validates the bull case scenario from the master report (DMD site activation within 1H26), slightly reducing clinical execution risk and shifting the narrative from a pure HBV option to a two-program catalyst map. However, first patient dosing is not yet confirmed, and the core investment thesis still hinges on the HBV biopsy data; DMD progress alone does not fundamentally change the risk-reward.